Stryker $1.65B Acquisition of Mako defines the desire for new innovative products by large med device
companies looking for growth in a healthcare environment slowed by reduced procedural volumes. Also did anyone notice extensive Microcutter line in Cardica's annual report? More under the hood then we were made aware form the press or conference calls! MicroCutter XCHANGE 30, 45 & 60, FLEXCHANGE 30 and XPRESS 30,45 & 60! The FLEXCHANGE name refers to the planned group of cartridge-based microcutter products with flexible shafts that will also include our proprietary “staple-on-a-strip” technology. The first product that is planned in this family would be the Microcutter FLEXCHANGE 30 with a 30 mm staple line length. We expect this product would be the first and only 5 mm stapling device available on the market with a flexible shaft and is being developed with up to 80 degrees of articulation as currently there are no other products on the market that have these characteristics. This device is planned to facilitate endoscopic procedures requiring cutting and stapling. Very cool!
From MLV - An analyst at the firm comments, "We think that once Cardica completes development of the MicroCutter product line, the Company will become a strong acquisition target. The existing stapling market is dominated by two large players and Cardica’s technology could either cement one of them as the market leader, or allow another player to enter the space with well-differentiated product entrants." Key question is was would be considered completed development of the product line? A CE Mark on The Exchange 30, 45 & 60, Express 30, 45 & 60 and Flexchange 30 or an FDA approval on the exchange 30? That is the question!